Related Experiment Video
Updated: Jun 25, 2026
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
A Single Institution Retrospective Review of Pancreatic Stereotactic Body Radiotherapy Outcomes
Aaron Jin1, Nam Nguyen2, Adrian Esterman3
1Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Journal of Medical Imaging and Radiation Oncology
|June 24, 2026
Summary
Stereotactic body radiotherapy (SBRT) offers improved local control for unresectable pancreatic cancer. This advanced radiotherapy technique demonstrates manageable toxicity, making it a promising treatment option.
Area of Science:
- Oncology
- Radiation Oncology
- Gastroenterology
Background:
- Pancreatic cancer has high mortality, necessitating improved therapies.
- Conventional radiotherapy is limited by dose constraints of surrounding organs.
- Stereotactic body radiotherapy (SBRT) enables higher doses for better local control.
Purpose of the Study:
- To evaluate the efficacy and safety of SBRT for unresectable pancreatic cancer.
- To assess local control and overall survival outcomes.
- To determine toxicity profiles associated with SBRT.
Main Methods:
- Eighty-seven patients with locally advanced, unresectable pancreatic adenocarcinoma received SBRT.
- SBRT utilized endoscopic fiducial seed guidance.
- Treatment involved concurrent chemotherapy or dose-escalated radiotherapy alone in 3-5 fractions.
Main Results:
- Median overall survival was 8 months with a median follow-up of 8 months.
- One-year local control rate was 75% among survivors.
- Most toxicities were mild (Grade 1-2), with no Grade 4 or higher events.
Conclusions:
- SBRT overcomes dose limitations of adjacent organs, enhancing local control.
- SBRT offers shorter treatment times compared to conventional radiotherapy.
- Manageable toxicity makes SBRT an appealing option for unresectable pancreatic cancer.
